Literature DB >> 16515905

Are allografts the biologic valve of choice for aortic valve replacement in nonelderly patients? Comparison of explantation for structural valve deterioration of allograft and pericardial prostheses.

Nicholas G Smedira1, Eugene H Blackstone, Eric E Roselli, Colleen C Laffey, Delos M Cosgrove.   

Abstract

OBJECTIVE: To compare explantation for structural valve deterioration in nonelderly patients after aortic valve replacement with stented bovine pericardial and cryopreserved allograft valves.
METHODS: From 1981 to 1985, 478 patients received pericardial prostheses during premarket approval; from 1987 to 2000, 744 patients received cryopreserved allografts. Mean age of patients receiving allografts was 49 +/- 12 years, and that of those receiving pericardial prostheses was 65 +/- 11 years; pericardial valves were used in 138 patients younger than age 60. Mean follow-up was 15 +/- 5.1 years for pericardial valves (4674 patient-years of follow-up) and 5.6 +/- 3.1 years for allografts (3892 patient years of follow-up). Multivariable hazard function methodology, age-group stratification, and propensity matching were used to compare age-specific explantation for structural valve deterioration.
RESULTS: Ninety-five pericardial valves and 46 allografts were explanted, and structural valve deterioration was the mechanism of failure in 74% and 59%, respectively. The risk of structural valve deterioration increased with younger age at implantation for both allografts (P = .07) and pericardial valves (P < .0001), with a similar magnitude of effect in patients age 50 years or younger (P = .5), 50 to 60 years (P = .7), and greater than 60 years (P = .9) and in propensity-matched pairs (P = .2). Thus, pericardial valves were as durable as allografts at all adult ages.
CONCLUSIONS: Structural valve deterioration is the most frequent cause of valve-related reoperation after both pericardial and allograft aortic valve replacement and is similarly age dependent, suggesting that pericardial valves may be appropriate for nonelderly as well as older persons.

Entities:  

Mesh:

Year:  2006        PMID: 16515905     DOI: 10.1016/j.jtcvs.2005.09.016

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  12 in total

Review 1.  Prosthetic valve selection for middle-aged patients with aortic stenosis.

Authors:  Joanna Chikwe; Farzan Filsoufi; Alain F Carpentier
Journal:  Nat Rev Cardiol       Date:  2010-11-02       Impact factor: 32.419

Review 2.  Surgical Treatment of Valvular Heart Disease: Overview of Mechanical and Tissue Prostheses, Advantages, Disadvantages, and Implications for Clinical Use.

Authors:  Amy G Fiedler; George Tolis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-02-05

3.  Mid- to long-term outcomes of cardiovascular tissue replacements utilizing homografts harvested and stored at Japanese institutional tissue banks.

Authors:  Soichiro Kitamura; Toshikatsu Yagihara; Junjiro Kobayashi; Hiroyuki Nakajima; Koichi Toda; Tomoyuki Fujita; Hajime Ichikawa; Hitoshi Ogino; Takeshi Nakatani; Shigeki Taniguchi
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

Review 4.  Decellularized matrices for cardiovascular tissue engineering.

Authors:  Francesco Moroni; Teodelinda Mirabella
Journal:  Am J Stem Cells       Date:  2014-03-13

5.  Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis.

Authors:  Jocelyn M Beach; Tomislav Mihaljevic; Lars G Svensson; Jeevanantham Rajeswaran; Thomas Marwick; Brian Griffin; Douglas R Johnston; Joseph F Sabik; Eugene H Blackstone
Journal:  J Am Coll Cardiol       Date:  2013-02-26       Impact factor: 24.094

Review 6.  Surgical treatment of aortic valve disease.

Authors:  Tirone E David
Journal:  Nat Rev Cardiol       Date:  2013-05-14       Impact factor: 32.419

Review 7.  Anticoagulation Management After Transcatheter and Surgical Valve Replacement.

Authors:  Ricardo Cigarroa; Sammy Elmariah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-11

8.  Totally biological composite aortic stentless valved conduit for aortic root replacement: 10-year experience.

Authors:  Manuel Galiñanes; Ayo Meduoye; Ignacio Ferreira; Andrzej Sosnowski
Journal:  J Cardiothorac Surg       Date:  2011-06-23       Impact factor: 1.637

9.  Special report: 26-year durability of a bioprosthesis implanted in a 21-year-old patient.

Authors:  Torulv Holst; Josef Reichert; Peter Haldenwang; Vadim Moustafine; Matthias Bechtel; Justus Strauch; Stephan Knipp
Journal:  Thorac Cardiovasc Surg Rep       Date:  2014-02-27

10.  A second-time percutaneous aortic-valve implantation for bioprosthetic failure.

Authors:  Pablo Codner; Abid Assali; Hana Vaknin Assa; Ran Kornowski
Journal:  Clin Case Rep       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.